Abstract:Malignant tumors and hypertension are both highly prevalent and fatal diseases and often coexist. In recent years, onco-hypertension has become an emerging field formed at the intersection of malignant tumors and hypertension. Its scope includes the comorbidity of malignant tumors and hypertension, hypertension induced by malignant tumors themselves and their treatment, and the impact of hypertension and its treatment on malignant tumors, aiming to clarify the underlying mechanisms and standardize clinical management. Therefore, this review elaborates the similarities and differences between onco-hypertension and essential hypertension, comorbidity mechanisms, clinical management strategies, and the relationship between hypertension, antihypertensive drugs and malignant tumors. It provides a reference for optimizing blood pressure management and improving prognosis in patients with onco-hypertension, which helps to open up new directions in the field of cardio-oncology.